Business
This section features DDW articles on the business side of pharma & drug discovery
Page 1 to 16 of 66 |     NEXT PAGE >
Improving Drug Development Productivity With Better Predictivity By Dr Lorna C. Ewart, et al. Summer 2018
Changing demands in global healthcare over the past 15 years have led to greater complexity and spiralling costs in drug development. The average price tag of taking a new drug from discovery to completion of Phase III clinical trials is now $2.87 billion (1), which means informed decisions need to be made early on about which compounds to pursue.

Read More

Disruptive Approaches To Accelerate Drug Discovery and Development (Part 1) By Ibis Sanchez- Serrano, Dr Tom Pfeifer and Dr Rathnam Chaguturu Spring 2018
This article is part 1 of 2, and covers tools, technologies and the core model of disruptive approaches to accelerate drug discovery and development.

Read More

Emerging Drug Discovery Alliance Models By Dr Swati Prasad, Mary Louise Bell & Dr Charles McOsker Winter 2017/18
The current environment for early-stage drug discovery and development is fluid and the probability of success continues to be challenging.

Read More

The Discoverome, Creative Destruction of Barriers for Faster to Patient Medicines R&D By Chris Molloy Spring 2017
Future medicines discovery begins and ends with patients. Its scope will no longer be limited by the walls of the lab and the moats of major pharma. It will be disease-led, highly collaborative and fast.

Read More

Filling The Drug Discovery Abyss - Novel Business Models to Push Through the Valley of Death By Dr Swati Prasad, Dr Charles McOsker, Professor Kathryn Chapman and Dr Michael Foley Winter 16/17
Over the past three years, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved around 200 novel drugs for human use (1,2). Not a large number considering the Pharmaceutical Research and Manufacturers of America (PhRMA) citation that for every 5,000 to 10,000 compounds that enter the pipeline, only one receives approval (3)

Read More

Digital Pharma - How Digital Is Reshaping The Pharma Arena By Ulrica Sehlstedt, Nils Bohlin, Fredrik de Mare and Richard Beetz Spring 2016
The pharmaceutical industry in the 20th and early 21st century has been in constant change, driven by both incremental and breakthrough innovations.

Read More

The Benefits of Pre-Competitive Collaboration in the Pharmaceutical Industry By Richard Holland Fall 2015
Pre-competitive collaboration allows a group of competing companies to come together to develop a solution for a problem that they all share, and from which none of them would gain a competitive advantage.

Read More

Valuation In Pharma Portfolio Management By Dr Michel Azoulay Winter 2015/16
Throughout the course of my career, I have been involved in a wide range of portfolio decisions and continue to be involved in them today. Over the years, it has been observed that despite cultural differences, pharma teams face similar problems.

Read More

Overcoming the Disruption Dip in the Aftermath of Mergers & Acquisitions By Roger Humphrey Fall 2015
M&A deals are disrupting the life science industry – and that’s good, mostly. Yet, when a company reshapes its facilities footprint in the wake of a consolidation, cost efficiency can be undermined by the dreaded ‘disruption dip’ in productivity. Here’s how to keep your workplaces and laboratories on track.

Read More

Therapeutic Drug Repurposing, Repositioning and Rescue Part II: Business Review By Dr Stephen Naylor, David M. Kauppi and Judge M. Schonfeld Spring 2015
There is an emerging consensus that the impact of Drug Repurposing, Repositioning and Rescue (DRPx) on the pharmaceutical industry is real and sustainable.

Read More

BioPharma and CROs Collaborating In Early Drug Discovery By Dr John Montana and Cornelis E.C.A. Hop Summer 2015
BioPharma and CROs are riding the latest wave – discovery research – together with a vigour and gusto that might have seemed implausible five years ago. How these collaborations are structured, and how well they function, can vary widely, though.

Read More

Misconduct in the biomedical sciences part 1: issues and causes. By Dr Gerald H. Lushington and Rathnam Chaguturu Spring 2015
Science pursues truth. Real advances in biomedical sciences improve our quality of life and save lives, but the path to these advances is cluttered with the distraction of irreproducible results – an affliction that has reached epidemic proportions and is now a global crisis spanning developed and developing countries alike, with much of the problem arising from scientific misconduct.

Read More

Misconduct in the biomedical sciences part 2: detection and prevention By Dr Gerald H. Lushington and Rathnam Chaguturu Summer 2015
Discovering safe and effective medicines, one of the greatest gifts to humanity, relies intensely upon the availability of detailed, unassailably accurate biomedical scientific knowledge.

Read More

The Chinese Biologics Drug Market: Demand and Execution By Dr Andy Tsun, Jia Li, Joanne Sun, Dr Michael Yu, Dr Yajie Li and Xiaolin Liu Spring 2015
In the past decade, China's drug market has been expanding in double-digit percentages. This has brought about a huge increase in local drug makers and has lured multinational pharmaceutical companies to develop, manufacture and commercialise their drug products in China.

Read More

Building New Models of Drug Discovery in Europe - The Innovative Medicines Initiative By Dr Angela Wittelsberger, Dr Hugh Laverty and Dr Michel Goldman Spring 2014
The discovery and development of a new medicine is time-consuming, risky and expensive. It often takes 10-15 years and an investment of on average >$1 billion for a compound to navigate its way along the drug discovery and development process – and only 8% of drug candidates entering clinical development make it to market and benefiting the patient (2).

Read More

Business
Page 1 to 16 of 66 |     NEXT PAGE >